LMT503

Lmito Therapeutics Inc. · Phase 1 active Small molecule

At a glance

Generic name	LMT503
Sponsor	Lmito Therapeutics Inc.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

LMT503 First-in-human SAD, MAD, and FE Study (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

LMT503 CI brief — competitive landscape report
LMT503 updates RSS · CI watch RSS
Lmito Therapeutics Inc. portfolio CI